HRAS and neoplasm: Similarly, a fibronectin type III domain-based RAS binding monobody (Khan et al., 2019b; Koide et al., 1998; Spencer-Smith et al., 2017, 2019) was shown to bind and inhibit the dimerization of both K- and H-RAS, and the overexpression of this monobody was shown to suppress tumor growth in mice (Khan et al., 2019b).